developed through disease-focused subsidiaries of BioTime. ReCyte Therapeutics is one such subsidiary focused on applying the Company's proprietary ReCyte™ technology to blood and vascular aging. ReCyte™ is a technology capable of reprogramming cells taken from aged patients back to an embryonic state such that all cell types can be produced genetically identical to the patient. It is also capable of resetting the telomere clock of cellular aging to make any type of young cells otherwise identical to aged patients. ReCyte's mission is to pioneer the application of this advance in gerontology to the largest unmet need in aging; namely cardiovascular and blood senescence.